Last 29 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 55.77 | 56.12 | 350.44 | 22.63 | 19.32 | 13.16 | 128.68 | 18.98 | 13.57 | 5.85 | 28.66 | 759.25 | 6.38 | 42.41 | 15.37 | 11.85 | — | 31.39 | 15.01 | 81.17 | 642.74 |
| — | +326.3% | +172.3% | +19.2% | +42.4% | +125.2% | +348.9% | -97.5% | +112.5% | -86.2% | +86.5% | +6306.1% | — | +35.1% | +2.4% | -85.4% | — | -16.6% | +58.2% | +34.0% | — | |
| P/S Ratio | 11.40 | 11.78 | 11.58 | 10.64 | 8.69 | 8.10 | 8.75 | 7.92 | 6.33 | 7.43 | 7.32 | 7.99 | 7.09 | 7.61 | 8.65 | 8.00 | 9.13 | 10.64 | 11.91 | 10.52 | 8.84 |
| — | +45.4% | +32.3% | +34.4% | +37.4% | +9.1% | +19.5% | -0.9% | -10.8% | -2.3% | -15.3% | -0.1% | -22.3% | -28.5% | -27.3% | -24.0% | +3.2% | +13.6% | +6.2% | -8.9% | +4.2% | |
| P/B Ratio | 3.88 | 3.32 | 3.19 | 2.70 | 2.23 | 2.05 | 2.13 | 1.84 | 1.45 | 1.64 | 1.61 | 1.84 | 1.68 | 1.70 | 1.90 | 2.23 | 2.17 | 2.34 | 2.45 | 2.33 | 1.99 |
| — | +61.7% | +49.7% | +46.9% | +53.2% | +25.5% | +32.1% | -0.1% | -13.4% | -3.9% | -14.9% | -17.4% | -22.7% | -27.3% | -22.6% | -4.5% | +9.1% | +10.9% | +2.5% | -13.4% | +1.2% | |
| P/FCF | 10.08 | 11.84 | 11.38 | 8.82 | 6.54 | 7.02 | 13.92 | 7.55 | 5.06 | 5.96 | 5.98 | 6.83 | 5.47 | 7.11 | 7.66 | 5.29 | 9.06 | 11.32 | 11.10 | 12.85 | 10.39 |
| — | +68.6% | -18.2% | +16.9% | +29.2% | +17.9% | +132.8% | +10.6% | -7.5% | -16.2% | -22.0% | +29.0% | -39.6% | -37.2% | -31.0% | -58.8% | -12.8% | -3.1% | -5.1% | +2.1% | +21.0% | |
| EV / EBITDA | 25.20 | 28.41 | 73.30 | 13.89 | 19.22 | 16.20 | 43.36 | 12.30 | 13.56 | 6.71 | 22.16 | 146.66 | 7.38 | 31.99 | 14.80 | 12.15 | — | 28.53 | 14.17 | 32.13 | 40.70 |
| — | +75.3% | +69.0% | +13.0% | +41.7% | +141.4% | +95.6% | -91.6% | +83.9% | -79.0% | +49.8% | +1107.0% | — | +12.1% | +4.4% | -62.2% | — | +29.4% | +43.9% | -4.4% | +114.9% | |
| EV / EBIT | 24.47 | 28.41 | 56.22 | 15.67 | 16.64 | 13.25 | 43.36 | 12.30 | 13.56 | 6.71 | 22.16 | 146.66 | 7.38 | 31.99 | 14.80 | 12.15 | — | 28.53 | 14.17 | 41.35 | 64.38 |
| — | +114.4% | +29.6% | +27.4% | +22.7% | +97.5% | +95.6% | -91.6% | +83.9% | -79.0% | +49.8% | +1107.0% | — | +12.1% | +4.4% | -70.6% | — | +11.5% | +61.8% | +2.8% | +329.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 91.0% | 60.2% | 99.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | -9.0% | -39.8% | -0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | 65.6% | 59.6% | 19.7% | 100.3% | 62.4% | 70.1% | 36.3% | 94.0% | 60.9% | 130.2% | 50.2% | -13.0% | 102.8% | 28.2% | 46.2% | 70.0% | -85.3% | 33.5% | 70.5% | 39.1% | 26.6% |
| — | -15.0% | -45.6% | +6.7% | +2.5% | -46.1% | -27.8% | +823.7% | -40.8% | +361.0% | +8.5% | -118.5% | +220.5% | -15.8% | -34.4% | +79.1% | -420.1% | -35.2% | -47.5% | -2.3% | -51.5% | |
| Net Margin | 32.4% | 21.0% | 2.7% | 46.8% | 34.4% | 47.3% | 5.2% | 41.9% | 35.1% | 96.3% | 19.0% | 0.8% | 82.9% | 13.4% | 42.3% | 49.8% | -80.6% | 24.9% | 56.8% | 9.2% | 1.4% |
| — | -55.6% | -49.1% | +11.5% | -1.8% | -50.9% | -72.5% | +4886.3% | -57.7% | +616.4% | -55.1% | -98.3% | +202.9% | -45.9% | -25.6% | +441.0% | -5972.0% | +43.0% | -28.5% | -23.7% | -95.4% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.7% | 1.5% | 0.2% | 3.0% | 2.2% | 3.0% | 0.3% | 2.4% | 2.0% | 5.4% | 1.0% | 0.0% | 5.0% | 0.7% | 2.3% | 3.5% | -4.6% | 1.4% | 3.0% | 0.5% | 0.1% |
| — | -50.9% | -42.0% | +26.8% | +9.6% | -44.6% | -69.9% | +4843.6% | -59.8% | +631.3% | -55.1% | -98.6% | +209.9% | -45.7% | -21.8% | +593.8% | -6071.5% | +39.7% | -32.0% | -27.5% | -95.6% | |
| ROA | 4.1% | 0.7% | 0.1% | 1.5% | 1.1% | 1.5% | 0.2% | 1.3% | 1.1% | 3.0% | 0.6% | 0.0% | 3.1% | 0.4% | 1.3% | 2.0% | -2.6% | 0.8% | 1.7% | 0.3% | 0.0% |
| — | -51.8% | -46.3% | +12.5% | -4.3% | -49.8% | -72.2% | +4425.2% | -62.6% | +596.8% | -54.6% | -98.5% | +216.0% | -45.7% | -23.2% | +577.8% | -6004.0% | +35.3% | -36.2% | -31.5% | -95.8% | |
| ROIC | 6.7% | 1.7% | 0.6% | 2.6% | 1.6% | 1.9% | 0.9% | 2.4% | 1.6% | 3.4% | 1.3% | -0.4% | 3.0% | 0.8% | 1.3% | 2.4% | -2.3% | 0.9% | 1.8% | 1.1% | 0.7% |
| — | -7.2% | -41.9% | +8.6% | +2.2% | -45.3% | -27.9% | +771.0% | -47.0% | +341.2% | +4.8% | -114.9% | +230.9% | -14.8% | -31.6% | +127.9% | -414.7% | -38.9% | -50.6% | -9.1% | -55.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.92 | 0.88 | 0.92 | 0.90 | 0.92 | 0.93 | 0.84 | 0.78 | 0.74 | 0.74 | 0.78 | 0.62 | 0.61 | 0.64 | 0.73 | 0.73 | 0.75 | 0.68 | 0.68 | 0.70 | 0.69 |
| — | -5.9% | +8.7% | +15.8% | +25.2% | +25.7% | +8.0% | +25.0% | +21.0% | +15.9% | +7.4% | -14.2% | -18.6% | -6.3% | +6.4% | +3.6% | +7.9% | +0.0% | +22.0% | +18.3% | +17.8% | |
| Debt / EBITDA | 5.73 | 24.05 | 66.73 | 14.13 | 22.98 | 20.93 | 50.23 | 15.27 | 19.03 | 8.72 | 31.23 | 153.64 | 8.02 | 36.47 | 17.89 | 12.81 | — | 26.59 | 13.19 | 31.51 | 44.57 |
| — | +14.9% | +32.8% | -7.5% | +20.8% | +140.1% | +60.8% | -90.1% | +137.2% | -76.1% | +74.6% | +1099.6% | — | +37.1% | +35.6% | -59.3% | — | +15.8% | +70.0% | +27.2% | +145.1% | |
| Current Ratio | 0.97 | 1.29 | 1.29 | 2.66 | 0.97 | 3.48 | 1.26 | 1.56 | 1.44 | 1.54 | 9.35 | 12.52 | 7.90 | 13.51 | 2.52 | 2.36 | 2.19 | 2.07 | 19.22 | 21.95 | 16.81 |
| — | -62.9% | +2.1% | +70.8% | -32.3% | +126.8% | -86.5% | -87.6% | -81.8% | -88.6% | +271.3% | +431.5% | +260.6% | +552.8% | -86.9% | -89.3% | -87.0% | -81.0% | +101.6% | +132.6% | +91.9% | |
| Quick Ratio | 0.97 | 1.29 | 1.29 | 2.66 | 0.97 | 3.48 | 1.26 | 1.56 | 1.44 | 1.54 | 9.35 | 12.52 | 7.90 | 13.51 | 2.52 | 2.36 | 2.19 | 2.07 | 19.22 | 21.95 | 16.81 |
| — | -62.9% | +2.1% | +70.8% | -32.3% | +126.8% | -86.5% | -87.6% | -81.8% | -88.6% | +271.3% | +431.5% | +260.6% | +552.8% | -86.9% | -89.3% | -87.0% | -81.0% | +101.6% | +132.6% | +91.9% | |
| Interest Coverage | 5.30 | 3.97 | 1.87 | 6.00 | 4.78 | 6.58 | 2.32 | 7.64 | 6.08 | 13.12 | 4.97 | 0.90 | 16.19 | 3.65 | 8.48 | 11.84 | -11.99 | 5.69 | 11.47 | 3.72 | 2.14 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RPRX stock.
Royalty Pharma plc's current P/E is 55.8x. The average P/E over the last 4 quarters is 112.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Royalty Pharma plc's current operating margin is 65.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Royalty Pharma plc's business trajectory between earnings reports.